About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 197 record(s)
Req # A-2019-001505
The letter that Health Canada sent September 5, 2019 to GENTÈS ET BOLDUC, PHARMACIENS, INC., authorizing the pharmacy operated by this company to produce cysteamine eye drops.Organization: Health Canada
February 2022
Req # A-2019-001506
All documentation in Health Canada's possession regarding the letter that Health Canada sent September 5, 2019 to GENTÈS ET BOLDUC, PHARMACIENS, INC., authorizing the pharmacy operated by this company to produce cysteamine eye dropsOrganization: Health Canada
February 2022
Req # A-2019-001781
All correspondence between Health Canada and the sponsor relating to any abbreviated new drug submission (ANDS) filed for a leuprolide acetate product, namely, any ANDS filed for the drug ZEULIDE, whether the ANDS was approved or not.Organization: Health Canada
February 2022
Req # A-2019-001942
The total amount of cannabis that Health Canada authorized for import and export into Canada in 2019, summarized by date, weight and the licence holder responsible.Organization: Health Canada
February 2022
Req # A-2020-000214
All records related to discussions of including sex and/or gender in any form of risk communication including, public advisories, Health Canada-issued Health Professional Communication: 'Dear Health Care Professional' Letter, Health Canada…Organization: Health Canada
February 2022
Req # A-2020-001718
Health Canada approved inner and outer labels for the below Drug Identification Numbers (DINs) and products DIN 02509075 REDESCA 30 MG / 0.3 ML DIN 02509083 REDESCA 40 MG / 0.4 ML DIN 02509091 REDESCA 60 MG / 0.6 ML DIN 02509105 REDESCA 80 MG / 0.8…Organization: Health Canada
February 2022
Req # A-2020-001792
All relevant documents pertaining to the investigation of Poulin's Pest Control Winnipeg for potential pesticide non-compliance at a 24-7 Intouch office space located at Unit 3-875 St. James St. The misuse was reported to Health Canada in late…Organization: Health Canada
February 2022
Req # A-2021-000026
Documentation related to Zytiga 500 mg, film-coated tablets (abiraterone acetate, MAH = Janssen Inc, DIN: 02457113), namely the Synopsis of preclinical Study TOX9587 (“1-month Repeated Dose Oral Toxicity Study of JNJ-212082-AAA in the Rat with…Organization: Health Canada
February 2022
Req # A-2021-000071
The status of various claims for exemptions under the Hazardous Materials Information Review Act, filed by Exaltexx Inc (this company has also recently changed its name to Advancing Chemistry Inc), and copies of the Notice of Filing and Exaltexx Inc…Organization: Health Canada
February 2022
Req # A-2021-000335
Any adverse events or reaction reports in connection with Nutricia North America’s product, Neocate.Organization: Health Canada
February 2022